Literature DB >> 27825696

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Elisa Pin1, Steven Stratton2, Claudio Belluco3, Lance Liotta4, Ray Nagle2, K Alex Hodge4, Jianghong Deng4, Ting Dong4, Elisa Baldelli4, Emanuel Petricoin4, Mariaelena Pierobon5.   

Abstract

The cross-talk between tumor epithelium and surrounding stromal/immune microenvironment is essential to sustain tumor growth and progression and provides new opportunities for the development of targeted treatments focused on disrupting the tumor ecology. Identification of novel approaches to study these interactions is of primary importance. Using laser capture microdissection (LCM) coupled with reverse phase protein microarray (RPPA) based protein signaling activation mapping we explored the molecular interconnection between tumor epithelium and surrounding stromal microenvironment in 18 prostate cancer (PCa) specimens. Four specimen-matched cellular compartments (normal-appearing epithelium and its adjacent stroma, and malignant epithelium and its adjacent stroma) were isolated for each case. The signaling network analysis of the four compartments unraveled a number of molecular mechanisms underlying the communication between tumor cells and stroma in the context of the tumor microenvironment. In particular, differential expression of inflammatory mediators like IL-8 and IL-10 by the stroma cells appeared to modulate specific cross-talks between the tumor cells and surrounding microenvironment.
Copyright © 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cross-talk; Kinase signaling; Laser capture microdissection; Prostate cancer; Reverse phase protein microarray; Tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 27825696      PMCID: PMC5423125          DOI: 10.1016/j.molonc.2016.09.007

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  51 in total

1.  Antibody validation by Western blotting.

Authors:  Michele Signore; K Alex Reeder
Journal:  Methods Mol Biol       Date:  2012

Review 2.  Reverse-phase protein microarrays: application to biomarker discovery and translational medicine.

Authors:  Amy VanMeter; Michele Signore; Mariaelena Pierobon; Virginia Espina; Lance A Liotta; Emanuel F Petricoin
Journal:  Expert Rev Mol Diagn       Date:  2007-09       Impact factor: 5.225

3.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

4.  Preparation and use of reverse protein microarrays.

Authors:  Elisa Pin; Giulia Federici; Emanuel F Petricoin
Journal:  Curr Protoc Protein Sci       Date:  2014-02-03

5.  Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology.

Authors:  Virginia Espina; Claudius Mueller; Lance A Liotta
Journal:  Methods Mol Biol       Date:  2011

6.  Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.

Authors:  Elisa Baldelli; Eric B Haura; Lucio Crinò; Douglas W Cress; Vienna Ludovini; Matthew B Schabath; Lance A Liotta; Emanuel F Petricoin; Mariaelena Pierobon
Journal:  Proteomics Clin Appl       Date:  2015-03-24       Impact factor: 3.494

Review 7.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

8.  Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.

Authors:  Núria de la Iglesia; Genevieve Konopka; Kah-Leong Lim; Catherine L Nutt; Jacqueline F Bromberg; David A Frank; Paul S Mischel; David N Louis; Azad Bonni
Journal:  J Neurosci       Date:  2008-06-04       Impact factor: 6.167

Review 9.  Targeting the tumor microenvironment: from understanding pathways to effective clinical trials.

Authors:  Hua Fang; Yves A Declerck
Journal:  Cancer Res       Date:  2013-08-02       Impact factor: 12.701

10.  Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors.

Authors:  Li Sui; Youyi Dong; Yasuo Watanabe; Fuminori Yamaguchi; Katsuyoshi Sugimoto; Masaaki Tokuda
Journal:  Oncol Rep       Date:  2006-04       Impact factor: 3.906

View more
  7 in total

1.  A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Authors:  Elisa Pin; Steven Stratton; Claudio Belluco; Lance Liotta; Ray Nagle; K Alex Hodge; Jianghong Deng; Ting Dong; Elisa Baldelli; Emanuel Petricoin; Mariaelena Pierobon
Journal:  Mol Oncol       Date:  2016-10-14       Impact factor: 6.603

2.  Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Authors:  G Aaron Hobbs; Nicole M Baker; Anne M Miermont; Ryan D Thurman; Mariaelena Pierobon; Timothy H Tran; Andrew O Anderson; Andrew M Waters; J Nathaniel Diehl; Bjoern Papke; Richard G Hodge; Jennifer E Klomp; Craig M Goodwin; Jonathan M DeLiberty; Junning Wang; Raymond W S Ng; Prson Gautam; Kirsten L Bryant; Dominic Esposito; Sharon L Campbell; Emanuel F Petricoin; Dhirendra K Simanshu; Andrew J Aguirre; Brian M Wolpin; Krister Wennerberg; Udo Rudloff; Adrienne D Cox; Channing J Der
Journal:  Cancer Discov       Date:  2019-10-24       Impact factor: 38.272

3.  Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Authors:  Maria Isabella Sereni; Elisa Baldelli; Guido Gambara; Antonella Ravaggi; K Alex Hodge; David S Alberts; Jose M Guillen-Rodriguez; Ting Dong; Maurizio Memo; Franco Odicino; Roberto Angioli; Lance A Liotta; Sergio L Pecorelli; Emanuel F Petricoin; Mariaelena Pierobon
Journal:  Br J Cancer       Date:  2017-06-29       Impact factor: 7.640

4.  Total glucosides of paeony inhibits lipopolysaccharide-induced proliferation, migration and invasion in androgen insensitive prostate cancer cells.

Authors:  Zhi-Hui Zhang; Dong-Dong Xie; Shen Xu; Mi-Zhen Xia; Zhi-Qiang Zhang; Hao Geng; Lei Chen; Da-Ming Wang; Wei Wei; De-Xin Yu; De-Xiang Xu
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

Review 5.  Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.

Authors:  Johnny R Ramroop; Mark N Stein; Justin M Drake
Journal:  Front Oncol       Date:  2018-02-16       Impact factor: 6.244

6.  PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine.

Authors:  Elisa Baldelli; K Alex Hodge; Guido Bellezza; Neil J Shah; Guido Gambara; Angelo Sidoni; Martina Mandarano; Chamodya Ruhunusiri; Bryant Dunetz; Maysa Abu-Khalaf; Julia Wulfkuhle; Rosa I Gallagher; Lance Liotta; Johann de Bono; Niven Mehra; Ruth Riisnaes; Antonella Ravaggi; Franco Odicino; Maria Isabella Sereni; Matthew Blackburn; Angela Zupa; Giuseppina Improta; Perry Demsko; Lucio Crino'; Vienna Ludovini; Giuseppe Giaccone; Emanuel F Petricoin; Mariaelena Pierobon
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

Review 7.  On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances.

Authors:  Yiwu Yan; Su Yeon Yeon; Chen Qian; Sungyong You; Wei Yang
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.